Health Care Article: Changes to Off-Label Prescribing Practices Under Medicare Part D
7/1/2006
Written by Mintz Levin attorneys Marie C. Infante and Stephen R. Bentfield for the Legal Corner of Oncology Issues, July/August 2006, this article discusses off-label treatments prescribed for cancer and the new oral anti-cancer medications that are currently on the market or are likely to receive market approval in the near future and why the off-label issue is taking on a new urgency.
Stephen is an associate in the firm's Washington office, practicing in the Health Section. Prior to joining Mintz Levin, Stephen was an attorney and law clerk at leading national and Washington, D.C. firms. He has substantial experience working on projects with attorneys in several practice areas in addition to health law, including labor and employment, bankruptcy, general litigation, and corporate law.
Marie is a member of the Health Section in the firm's Washington D.C. office. In addition to more than 16 years of health care law experience, she also has extensive provider operations experience as a professional nurse and a health care executive.
